Publicaciones en colaboración con investigadoras/es de Hospital Sierrallana (83)

2024

  1. SLESIS-R: an improved score for prediction of serious infection in patients with systemic lupus erythematosus based on the RELESSER prospective cohort

    Lupus Science and Medicine, Vol. 11, Núm. 1

2023

  1. Central nervous system involvement in systemic lupus erythematosus: Data from the Spanish Society of Rheumatology Lupus Register (RELESSER)

    Seminars in Arthritis and Rheumatism, Vol. 58

  2. Venous thromboembolism characteristics, treatment and outcomes in young adults: findings from the Registro Informatizado de Enfermedad TromboEmbólica registry

    Journal of Thrombosis and Haemostasis, Vol. 21, Núm. 10, pp. 2811-2823

2022

  1. Antimalarials exert a cardioprotective effect in lupus patients: Insights from the Spanish Society of Rheumatology Lupus Register (RELESSER) analysis of factors associated with heart failure

    Seminars in Arthritis and Rheumatism, Vol. 52

  2. Effectiveness and safety of dapagliflozin in real-life patients: data from the DAPA-RWE Spanish multicentre study

    Drugs in Context, Vol. 11

  3. Factors associated with atherosclerosis in radiographic and non-radiographic axial spondyloarthritis. A multicenter study on 838 patients

    Seminars in Arthritis and Rheumatism, Vol. 55

  4. Statin use and 30-day mortality in patients with acute symptomatic pulmonary embolism

    Journal of Thrombosis and Haemostasis, Vol. 20, Núm. 8, pp. 1839-1851

2021

  1. Body mass index and disease activity in chronic inflammatory rheumatic diseases: Results of the cardiovascular in rheumatology (CARMA) project

    Journal of Clinical Medicine, Vol. 10, Núm. 3, pp. 1-10

  2. Do all antiphospholipid antibodies confer the same risk for major organ involvement in systemic lupus erythematosus patients?

    Clinical and Experimental Rheumatology, Vol. 39, Núm. 3, pp. 555-563

  3. European registry on helicobacter pylori management: Effectiveness of first and second-line treatment in Spain

    Antibiotics, Vol. 10, Núm. 1, pp. 1-15

  4. Timing and characteristics of venous thromboembolism after noncancer surgery

    Journal of Vascular Surgery: Venous and Lymphatic Disorders, Vol. 9, Núm. 4, pp. 859-867.e2

  5. Treatment with tofacitinib in refractory psoriatic arthritis: A national multicenter study of the first 87 patients in clinical practice

    Journal of Rheumatology, Vol. 48, Núm. 10, pp. 1552-1558

2020

  1. Anti-il-6 receptor tocilizumab in refractory graves’ orbitopathy: National multicenter observational study of 48 patients

    Journal of Clinical Medicine, Vol. 9, Núm. 9, pp. 1-15

  2. Antiphospholipid syndrome (APS) in patients with systemic lupus erythematosus (SLE) implies a more severe disease with more damage accrual and higher mortality

    Lupus, Vol. 29, Núm. 12, pp. 1556-1565

  3. Combination of Bismuth and Standard Triple Therapy Eradicates Helicobacter pylori Infection in More than 90% of Patients

    Clinical Gastroenterology and Hepatology, Vol. 18, Núm. 1, pp. 89-98

2019

  1. Altered Th17/treg ratio in peripheral blood of systemic lupus erythematosus but not primary antiphospholipid syndrome

    Frontiers in Immunology, Vol. 10, Núm. MAR

  2. Comparative Study of Infliximab Versus Adalimumab in Refractory Uveitis due to Behçet's Disease: National Multicenter Study of 177 Cases

    Arthritis and Rheumatology, Vol. 71, Núm. 12, pp. 2081-2089

  3. Comparison of seven prognostic tools to identify low-risk pulmonary embolism in patients aged <50 years

    Scientific Reports, Vol. 9, Núm. 1

  4. Pure Membranous Lupus Nephritis: Description of a Cohort of 150 Patients and Review of the Literature

    Reumatologia Clinica, Vol. 15, Núm. 1, pp. 34-42

  5. Relationship between damage and mortality in juvenile-onset systemic lupus erythematosus: Cluster analyses in a large cohort from the Spanish Society of Rheumatology Lupus Registry (RELESSER)

    Seminars in Arthritis and Rheumatism, Vol. 48, Núm. 6, pp. 1025-1029